Anais da Academia Brasileira de Ciências (May 2024)

In silico analysis of non-structural protein 12 sequences from SARS-COV-2 found in Manaus, Amazonas, Brazil, reveals mutations linked to higher transmissibility

  • FERNANDO B. ZANCHI,
  • GABRIEL EDUARDO M. FERREIRA,
  • LUIS ANDRÉ M. MARIÚBA,
  • JULIANE C. GLÓRIA,
  • VALDINETE A. DO NASCIMENTO,
  • VICTOR C. DE SOUZA,
  • ANDRÉ DE LIMA G. CORADO,
  • FERNANDA O. DO NASCIMENTO,
  • ÁGATHA KÉLLY A. DA COSTA,
  • DÉBORA CAMILA G. DUARTE,
  • GEORGE ALLAN V. DA SILVA,
  • MATILDE DEL CARMEN C. MEJÍA,
  • KARINA P. PESSOA,
  • LUCIANA MARA F. GONÇALVES,
  • MARIA JÚLIA P. BRANDÃO,
  • MICHELE S. DE JESUS,
  • MARINEIDE S. DA SILVA,
  • CRISTIANO F. DA COSTA,
  • FELIPE G. NAVECA

DOI
https://doi.org/10.1590/0001-3765202420231336
Journal volume & issue
Vol. 96, no. 2

Abstract

Read online

Abstract The disease coronavirus COVID-19 has been the cause of millions of deaths worldwide. Among the proteins of SARS-CoV-2, non-structural protein 12 (NSP12) plays a key role during COVID infection and is part of the RNA-dependent RNA polymerase complex. The monitoring of NSP12 polymorphisms is extremely important for the design of new antiviral drugs and monitoring of viral evolution. This study analyzed the NSP12 mutations detected in circulating SARS-CoV-2 during the years 2020 to 2022 in the population of the city of Manaus, Amazonas, Brazil. The most frequent mutations found were P323L and G671S. Reports in the literature indicate that these mutations are related to transmissibility efficiency, which may have contributed to the extremely high numbers of cases in this location. In addition, two mutations described here (E796D and R914K) are close and have RMSD that is similar to the mutations M794V and N911K, which have been described in the literature as influential on the performance of the NSP12 enzyme. These data demonstrate the need to monitor the emergence of new mutations in NSP12 in order to better understand their consequences for the treatments currently used and in the design of new drugs.

Keywords